Mayukh Sukhatme Sells 17,519 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 17,519 shares of the firm’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $37.30, for a total value of $653,458.70. Following the sale, the insider owned 18,630,739 shares of the company’s stock, valued at $694,926,564.70. This represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 21st, Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock. The stock was sold at an average price of $36.48, for a total value of $5,280,698.88.
• On Wednesday, August 19th, Mayukh Sukhatme sold 172,899 shares of Roivant Sciences stock. The stock was sold at an average price of $37.17, for a total value of $6,426,655.83.
• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total value of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The stock was sold at an average price of $36.73, for a total value of $5,029,879.66.

Roivant Sciences Stock Down 1.5%

ROIV stock opened at $36.30 on Friday. The stock’s 50 day moving average is $34.61 and its two-hundred day moving average is $30.43. Roivant Sciences Ltd. has a 52-week low of $11.60 and a 52-week high of $37.97. The company has a market capitalization of $26.22 billion, a PE ratio of -68.49 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The company had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. As a group, sell-side analysts anticipate that Roivant Sciences Ltd. will post -2 EPS for the current year.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently made changes to their positions in the company. SBI Securities Co. Ltd. boosted its holdings in Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares during the period. Allworth Financial LP increased its stake in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares during the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of Roivant Sciences during the fourth quarter worth $47,000. Parallel Advisors LLC raised its holdings in shares of Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after purchasing an additional 520 shares during the period. Finally, CIBC Private Wealth Group LLC lifted its position in shares of Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after buying an additional 2,665 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ROIV shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Roivant Sciences in a research note on Wednesday. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research report on Thursday, August 6th. Citigroup upped their target price on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Guggenheim increased their price target on shares of Roivant Sciences from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.14.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.